Clinical Research Directory
Browse clinical research sites, groups, and studies.
Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women
Sponsor: Mayo Clinic
Summary
In postmenopausal women, obesity increases the risk of physical function decline, premature aging, and vascular dysfunction. Semaglutide and tirzepatide are potent obesity medications. The goal is to determine the effect of weight loss induced by the new generation of GLP-1 receptor agonists on physical function, aging biomarkers, and vascular function in postmenopausal women with obesity.
Key Details
Gender
FEMALE
Age Range
46 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-05-01
Completion Date
2027-03-31
Last Updated
2025-07-09
Healthy Volunteers
No
Interventions
semaglutide or tirzepatide
Semaglutide and tirzepatide will be dosed as per prescription labels
Lifestyle modification intervention
All participants will be recommended the following: 1) low-calorie diet based on their predicted by Harris Benedict resting energy expenditure minus 500 kcal per day; 2) physical activity: a goal of 10,000 steps or more per day; 3) exercise: a goal of 150 minutes or more of moderate-intensity aerobic activity (cardiovascular exercise) per week; 4) limited consumption of liquid calories (i.e. sodas, juices, alcohol, etc.).
Locations (1)
Mayo Clinic in Florida
Jacksonville, Florida, United States